



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
Stewart D. Lyman and M. Patricia Beckmann

Attorney Docket No.: 2813-1

#121C
Davis
6-7-00

Serial No.: 08/994,468

Technology Center: 1633

Filed: December 19, 1997

Examiner: J. Kerr

CPA Filed: May 26, 2000

For: MEDIUM CONTAINING FLT3 LIGAND FOR
CULTURING HEMATOPOIETIC CELLS

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.56(d)

Box CPA
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated February 29, 2000 (Paper No. 10), and pursuant to Rule 111 of the Rules of Practice, Applicants offer the following remarks and proposed amendments. Reconsideration of the above-captioned application is respectfully requested. Enclosed please find a request for a request for a Continued Prosecution Application, including the appropriate fee, and an article by Anderson, W.F. published in Science 288:627-629 (2000) [attached as "Exhibit A" to Amendment].

Amendments

In the claims:

Please amend the claims as follows.

- Sub E → 1. (amended) A hematopoietic cell expansion media comprising cell growth media[,] and flt3-L [alone or in combination with a cellular growth factor], wherein the flt3-L [and the growth factor are] is in an amount sufficient to cause hematopoietic cell expansion.
- C! 2. (amended) A method for expanding hematopoietic cells comprising contacting the cells with flt3-L [alone or in combination with a cellular growth factor], wherein the flt3-L [and the growth factor are] is in an amount sufficient to cause hematopoietic cell expansion.